Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 1 of 43 
Protocol Template Effective: 07 JAN 2015   
RILEY M. BOVE  
Clinical Research Protocol  
BAZEDOXIFENE ACETATE  AS A REMYELINATING THERAPY FOR 
PATIENTS WITH MULTIP LE SCLEROSIS  
Protocol Number:  0003 
Version Date:  08/27/2019 
Investigational Product:  Bazedoxifene  
IND Number:  138495  
Development Phase:  Phase II  
Sponsor:  Riley Bove, MD  
675 Nelson Rising Lane  
Weill Institute for the Neurosciences  
San Francisco, CA 94158  
Funding Organization:  Sherak Foundation  
Principal Investigator:  Name:    Riley Bove , MD  
Telephone:  (415) 595-2795  
Fax:  N/A 
E-mail:  riley.bove @ucsf.edu  
Medical Monitor:  Name:  Jeffrey Gelfand, MD   
Telephone:  (415) 680 -4900  
Fax:  N/A 
E-mail:  Jeffrey.Gelfand@ucsf.edu  
 
Approval:  
Riley M Bove, MD Assistant Professor of Neurology   08.27.2019 
PI or Sponsor Signature (Name and Title)   Date  
This confidential information about an investigational product is provided for the exclusive use of 
investigators of this product and is subject to recall at any time.  The information in this document 
may not be disclosed unless federal or state law or re gulations require such disclosure.  Subject to the 
foregoing, this information may be disclosed only to those persons involved in the study who have a 
need to know, with the obligation not to further disseminate this information.   
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 2 of 43 
Protocol Template Effective: 07 JAN 2015  PROTOCOL AGREEMENT  
 
I have read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study subjects enrolled under my supervision and 
providing  Riley M. Bove with complete and timely information, as outli ned in the 
protocol.  It is understood that all information pertaining to the study will be held strictly 
confidential and that this confidentiality requirement applies to all study staff at this site. 
Furthermore, on behalf of the study staff and myself, I agree to maintain the procedures 
required to carry out the study in accordance with accepted GCP principles and to abide 
by the terms of this protocol.  
 
Protocol Number:  0002  
 
Protocol Title:  BAZEDOXIFENE ACETATE AS A REMYELINATING THERAPY 
FOR PATIENTS WITH MULTIPLE SCLEROSIS  
 
Protocol Date:  08/06 /2019  
 
Riley M Bove, MD   08.27.2019  
Investigator Signature   Date  
Riley M. Bove, MD, Assistant Professor of Neurology  
Print Name and Title  
Site #    
Site Name  Weill Institute for the Neurosciences, University of California, San 
Francisco  
Address  675 Nelson Rising Lane  
 San Francisco, CA 94158  
  
  
Phone Number  415.595.2795  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 3 of 43 
Protocol Template Effective: 07 JAN 2015  TABLE OF CONTENTS  
 
1 BACKGROUND  ................................ ................................ ................................ ..................  4 
       1.1 Overview of Non -Clinical Studies  ................................ ................................ ...............  13 
1.2 Overview of Clinical Studies  ................................ ................................ .......................  13 
2 STUDY RATIONALE  ................................ ................................ ................................ ........  14 
2.1 Risk /  Benefit Assessment  ................................ ................................ ...........................  14 
3 STUDY OBJECTIVES  ................................ ................................ ................................ ....... 15 
3.1 Primary Objective  ................................ ................................ ................................ ........  15 
3.2 Secondary Objectives  ................................ ................................ ................................ .. 15 
4 STUDY DESIGN  ................................ ................................ ................................ .................  15 
4.1 Study Overview  ................................ ................................ ................................ ...........  15 
5 CRITERIA FOR EVALUAT ION  ................................ ................................ ......................  16 
5.1 Primary Efficacy Endpoint  ................................ ................................ ..........................  16 
5.2 Secondary Efficacy Endpoints  ................................ ................................ .....................  16 
5.3 Safety Evaluations  ................................ ................................ ................................ ....... 20 
6 SUBJECT SELECTION  ................................ ................................ ................................ ..... 22 
6.1 Study Population  ................................ ................................ ................................ ..........  22 
6.2 Inclusion Criteria  ................................ ................................ ................................ .........  22 
6.3 Exclusion Criteria  ................................ ................................ ................................ ........  22 
7 CONCURRENT MEDICATIO NS ................................ ................................ ....................  23 
7.1 Allowed  ................................ ................................ ................................ ........................  23 
7.2 Prohibited  ................................ ................................ ................................ .....................  23 
8 STUDY TREATMENTS  ................................ ................................ ................................ ..... 23 
8.1 Method of Assigning Subjects to Treatment Groups ................................ ...................  23 
8.2 Blinding  ................................ ................................ ................................ .......................  23 
8.3 Test and Control Formulation  ................................ ................................ ......................  24 
8.4 Supply of Study Medication at the Site  ................................ ................................ ....... 25 
8.5 Study Medication Accountability  ................................ ................................ ................  26 
8.6 Measures of Treatment Compliance  ................................ ................................ ............  26 
9 STUDY PROCEDURES AND  GUIDELINES  ................................ ................................ . 26 
9.1 Clinical Assessments  ................................ ................................ ................................ ... 26 
9.2 Clinical Laboratory Measurements  ................................ ................................ .............  29 
10 EVALUATIONS BY VISIT  ................................ ................................ ...............................  29 
10.1 Visit 1 ( Screening ) ................................ ................................ ................................ ....... 29 
10.2 Visit 2 ( Baseline ) ................................ ................................ ................................ .........  30 
10.3 Visit 3 ( Follow up 1, 3 -months )................................ ................................ ...................  30 
10.4 Visit 4 ( Follow up 2, 6 -months )................................ ................................ ...................  31 
10.5 Early Withdrawal Visit  ................................ ................................ ................................  31 
11 ADVERSE EXPERIENCE R EPORTING AND DOCUMEN TATION  ........................  31 
11.1 Adverse Events  ................................ ................................ ................................ ............  31 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 4 of 43 
Protocol Template Effective: 07 JAN 2015  11.2 Serious Adverse Experiences (SAE)  ................................ ................................ ...........  33 
11.3 Medical Monitoring  ................................ ................................ ................................ ..... 34 
12 DISCONTINUATION AND RE PLACEMENT OF SUBJECT S ................................ ... 34 
12.1 Withdrawal of Subjects  ................................ ................................ ................................  34 
12.3 Replacement of Subjects  ................................ ................................ ..............................  35 
13 PROTOCOL VIOLATIONS  ................................ ................................ ..............................  35 
14 DATA SAFETY MONITORI NG ................................ ................................ .......................  35 
15 STATISTICAL METHODS AND CONSIDERATIONS  ................................ ................  37 
15.1 Data Sets Analyzed  ................................ ................................ ................................ ...... 37 
15.2 Demographic and Baseline Characteristics  ................................ ................................ . 37 
15.3 Analysis of Primary Endpoint ................................ ................................ ......................  37 
15.4 Analysis of Secondary Endpoints  ................................ ................................ ................  37 
15.5 Interim Analysis  ................................ ................................ ................................ ...........  37 
15.6 Sample Size and Randomization  ................................ ................................ .................  37 
16 DATA COLLECTION, RET ENTION AND MONITORIN G ................................ ........  38 
16.1 Data Collection Instruments  ................................ ................................ ........................  38 
16.2 Data Management Procedures  ................................ ................................ .....................  38 
16.3 Data Quality Control and Reporting  ................................ ................................ ............  38 
16.4 Archival of Data ................................ ................................ ................................ ...........  38 
16.5 Availability and Retention of Investigational Records  ................................ ................  38 
16.6 Monitoring  ................................ ................................ ................................ ...................  39 
16.7 Subject Confidentiality  ................................ ................................ ................................  39 
17 ADMINISTRATIVE, ETHI CAL, REGULATORY CONS IDERATIONS  ...................  39 
17.1 Protocol Amendments ................................ ................................ ................................ .. 39 
17.2 Institutional Review Boards and Independent Ethics Committees  ..............................  39 
17.3 Informed Consent Form  ................................ ................................ ...............................  40 
17.4 Publications  ................................ ................................ ................................ ..................  40 
17.5 Investigator Responsibilities  ................................ ................................ ........................  40 
 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 5 of 43 
Protocol Template Effective: 07 JAN 2015  LIST OF ABBREVIATION S 
 
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BUN  blood urea nitrogen  
BZA  Bazedoxifene acetate  
CFR  Code of Federal Regulations  
CVLT -II California Verbal Learning Test -II 
eCRF  Electronic Case Report F orm 
DMC  Data Monitoring Committee  
DSMB  Data Safety Monitoring Board  
EAE  Experimental Autoimmune Encephalomyelitis   
EDSS  Expanded Disability Status Scale  
EEG  Electroencephalogram  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
HPLC -MS/MS  High -performance Liquid Chromatographic -tandem mass 
spectrometric method  
ICF informed consent form  
ICH  International Conference on Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IV intravenous  
LDH  lactate dehydrogenase  
mEq  milliequivalent  
MFIS  Modified Fatigue Impact Scale  
MfVEP  Multi Focal Visual Evoked Potential  
MRI  Magnetic Resonance Imaging  
MS Multiple Sclerosis  
MSWS -12 Multiple Sclerosis Walking Scale  
OCT  Optical Coherence Tomography  
OPC  Oligodendrocyte progenitor cells  
PI Principal Investigator  
RNFL  Retinal Nerve Fiber Layer  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 6 of 43 
Protocol Template Effective: 07 JAN 2015  RRMS  Relapsing Remitting Multiple Sclerosis  
SAE  serious adverse experience  
SDMT  Symbol Digit Modality Test  
SERM  Selective Estrogen Receptor Modulator  
T25W  Timed 25 -foot Walk  
TUG  Timed -Up-and-Go  
VEP  Visual Evoked Potential  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 7 of 43 
Protocol Template Effective: 07 JAN 2015  PROTOCOL SYNOPSIS  
TITLE  Bazedoxifene acetate as a remyelinating therapy for patients with MS  
  SPONSOR  Dr. Riley M Bove  
  FUNDING 
ORGANIZATION  Sherak foundation  
NUMBER OF SITES  1 
  RATIONALE  Multiple Sclerosis (MS) is a chronic neurologic disorder characterized by 
the loss of myelin, which results in disruption of nerve signal, damage to 
axons, and, ultimately, neurodegeneration.  In order to treat MS, new 
methods for promoting repair (remyeli nation) are sorely needed.   
There is a strong preclinical (including EAE)7 and epidemiologic rationale 
for investigating the remyelinating potential of estrogenic compounds, 
including evidence of endogenous (puberty, postpartum period s)8 and 
exogenous hormonal influences on MS risk9-14 and course.15,16 MS affects 3 
times more women than men, and disease course in women appears overall 
less aggressive (on MRI, fewer T2 -hyperintense demyelinated lesions 
develop into axonal destruction visualized as hypointense T1 “black 
holes ”8,17).   
BZA, a third -generation SERM with extensive sa fety data in humans, was 
identified in a novel high -throughput screen (BIMA screen) for compounds 
capable of promoting remyelination.  Subsequent analysis validated BZA ’s 
remyelinating effect in vitro and in vivo  following demyelinating insult.  
Given stro ng pre -clinical support for BZA ’s remyelinating potential, and the 
clinical success of other compounds identified using the BIMA screen 
(Green et al., 2017), we propose the investigation of BZA as a remyelinating 
therapy in MS.   
  STUDY DESIGN  This is a single -center, double blind, randomized, c ontrolled, delayed -start 
Phase 2  clinical trial investigating the remyelinating effects of BZA relative 
to placebo.  
  PRIMARY 
OBJECTIVE  The primary objective is to evaluate the efficacy of BZA relative to placebo 
for reducing P100 latencies on full field transient pattern reversal visual 
evoked potentials at 90 days in a do uble-blinded trial (1st 90 days  in Group 
A versus 1st 90 days  of Group B.)  
  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 8 of 43 
Protocol Template Effective: 07 JAN 2015  SECONDARY 
OBJECTIVES  ● The first key secondary objective is to assess  whether latency delay at 180 
days decreases to a greater extent in Group A (exposed to BZA for 90 days 
during both Stage 1 and Stage 2) when compared to Group B (exposed to 
placebo during Stage 1 and BZA for only 90 days during Stage 2).  
● The second key  secondary objective is to demonstrate the tolerability of 
BZA in this population. This will include special focus with regards to 
fatigue as this is a major symptom for patients suffering from multiple 
sclerosis.  
● The third key secondary ob jective is to document the safety of BZA in this 
population of patients.  
● The fourth key secondary objective of this study is to help assess which 
secondary and tertiary outcomes are likely to be informative for future 
remyelin ating trials in multiple scl erosis.  
 
  NUMBER OF 
SUBJECTS  50 
  SUBJECT 
SELECTION  
CRITERIA  Inclusion Criteria : 
1. Relapsing remi tting Multiple Sclerosis by 2017  Revised 
McDonald Criteria  
2. Women aged 45 -65 or 40+ post -menopausal . 
3. Latency delay > 118 milliseconds on baseline full -field transient 
pattern reversal VEP in at least one  eye (electrophysiological 
evidence of demyelination)  
4. RNFL > 70 microns on SD -OCT in the same eye meeting criteria 
for latency delay (sufficient axons)  
5. Stable immunomodulatory therapy – no switch or planned switch 
in > 6 months and no change in  doses in 30 days prior to screening  
6. Use of contraceptive method with ≤1% failure rate  during period 
of trial if premenopausal  
7. Understand and sign informed consent.  
8. EDSS 0 -6.0 (inclusive)  
 
Exclusion Criteria : 
1. Multiple Sclerosis disease duration > 25 years  
2. Optic neuritis in prior 6 months  
3. Known optic neuritis in involved eye ≥ 10 years ago  
4. Major ophthalmologic disease/Concomitant ophthalmologic 
disorders (e.g. diabetes, macular d egeneration, glaucoma, severe 
myopia, etc.).  
5. Myopia > -7 Diopters (severe myopia)  
6. Disc hemorrhages in qualifying eye  
7. No light perception in qualifying eye  
8. Simultaneous bilateral optic neuritis  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 9 of 43 
Protocol Template Effective: 07 JAN 2015  9. Cotton wool spots in qualifying eye  
10. Macular star in qualifyin g eye  
11. History of significant cardiac conduction block  
12. History of cancer  (except non -melanoma skin cancer)  
13. Suicidal ideation or behavior in 6 months prior to baseline  
14. Pregnancy, breastfeeding, or planning to become pregnant  
15. Included with other study proto col simultaneously without prior 
approval  
16. Concomitant  or prior  use of any other putative remyelinating 
therapy as determined by investigator , including but not limited to 
Clemastine, Duavee, and Tamoxifen.   
17. Serum creatinine > 1.5mg/dL; AST, ALT, or alkaline phosphatase > 
2 times the upper limit of normal   
18. History of drug or alcohol abuse within the past year  
19. Untreated B12 deficiency (as determined by B12 serological 
assessments and metabolites including methylmalonic acid [MMA] 
and homocysteine) or untreated hypothyroidism   
20. Clinically significant cardiac, metabolic, hematologic, hepatic, 
immunologic, urologic, endocrinologic, neurologic, pulmonary, 
psychiatric, dermatologic, allergic, renal or o ther major diseases that 
in the PI ’s judgement may affect interpretation of study results or 
patient safety.  
21. History of or presence of clinically significant medical illness or 
laboratory abnormality that, in the opinion of the investigator would 
preclude  participation in the study.   
22. Patients whose lack of mobility exposes them to an increased 
risk of venous thromboembolism  
23. Patients with undiagnosed uterine bleeding  
24. Patients with unknown, suspected or past history of breast 
cancer  
25. Patients with known or s uspected estrogen -dependent 
neoplasia  
26. Patients with active or a past history of venous 
thromboembolism  
27. Patients with active or a past history of arterial 
thromboembolism  
28. Patients with known protein C, protein S, or antithrombin 
deficiency or other known th rombophilic disorders  
29. Patients with hypersensitivity (angioedema, anaphylaxis) to 
estrogens, bazedoxifene, or any ingredients  
30. Patients with known hepatic impairment or disease  
  
TEST PRODUCT, 
DOSE, AND ROUTE 40mg of bazedoxifene acetate (Conbriza)   
Product will be taken daily via oral administration of 2 20mg Conbriza 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 10 of 43 
Protocol Template Effective: 07 JAN 2015  OF 
ADMINISTRATION  tablets for the  duration of treatment period (180 days  for ‘Early -start’ group 
and 90 days  for ‘Delayed -start’ group).   Tablets will be over -encapsulat ed in 
gelatin capsules for proper blinding.  
  CONTROL 
PRODUCT, DOSE 
AND ROUTE OF 
ADMINISTRATION  Microcrystalline cellulose placebo  
Product will be taken daily via oral administration  of 2 tablets  for duration 
of the treatment period (first 90 days of ‘Delayed -start’ group ONLY).   
Tablets will be over -encapsulated in gelatin capsules for proper blinding.  
  DURATION OF 
SUBJECT 
PARTICIPATION 
AND DURATION OF 
STUDY  Subjects will be on study for up to  200 days   
Screening:  2 weeks  
Treatment:   6 months  
The total duration of the study is exp ected to be 24  months, which includes  
18 months for subject recruitment.  
E  CONCOMMITANT 
MEDICATIONS  Allowed: MS disease modifying and symptomatic therapies, 
antidepressants (no adjustments within 2 months of baseline visit)  
Prohibited: hormone therapies (estrogen, testosterone, progesterone), hot 
flash therapies; lamotrigine, oxcarbazepine  
  EFFICACY 
EVALUATIONS  This study includes the following efficacy assessments:  
• Detailed neurological examination, including the determination 
of EDSS  score, will take place at the baseline and 6-month  
visits.   
• Magnetic Resonance Imaging (MRI) scans will be performed at 
the bas eline , 3-month, & 6 -month  visits.   
• High and Low Contrast Visual Acuity (2.5% ETDRS) will be 
assessed at every visit.   
• Optical Coherence Tomography (OCT) will be performed at 
screening, baseline, and 6 -month visits .   
• Full-field Visual Evoked Potential wi ll be performed at every 
visit.     
• Cone contrast testing will be performed at baseline and 6 month 
visits.  
 Note: Prior to each visit, participants should be reminded to bring with 
them any corrective lenses that they use on a regular basis for reading, 
distance, or both.  If the participant does not have or if they forget their 
corrective lenses, a pair of trial lenses will be provided during the visit.   
 
PRIMARY ENDPOINT  Remyelination assessed by the reduction of P100 VEP latency  
SECONDARY 
ENDPOINTS  [Imaging]: Whole brain MTR, white matter MTR, white matter fractional 
anisotropy (FA), and MWF.  
[Functional]: Low -contrast letter acuity (LCLA)  
OTHER 
EVALUATIONS   
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 11 of 43 
Protocol Template Effective: 07 JAN 2015  SAFETY 
EVALUATIONS  Phone call at week 6 to see if patient is experiencing any unacceptable side 
effects.  
When approximately 50% of patients have completed the study through 
Study Visit 2 (total visit 3), an interim analysis for safety will be conducted 
by the PI. Serious adverse events will be monitored by the committee on an 
ongoing basis throughout the study.  
Incidence of adverse events.  
PLANNED INTERIM 
ANALYSES  When approximately 50% of patients have completed the study through 
Study Visit 2 (total visit 3), an interim analysis for safety will be conducted 
by the PI. Serious adverse events will be monitored by the committee on an 
ongoing  basis throughout the study.  
 
  STATISTICS  
Primary Analysis Plan  Data will be analyzed per protocol utilizing an intention to treat approach 
including all patients randomized to the study for the principal analysis. Loss 
to follow up will be accounted for using standard statistical methods. The 
principal analysis will be performed using mixed effects linear regression 
model controlling for clustering by eye.  
 
Rationale for Number 
of Subjects  With 25  patients per group the study has 90% power to detect a 50% relative 
reduction in latency with BZA compared to placebo at the 3 -month outcome 
for group 1 assuming a two -sided test with alpha = 0.05.  
Study size may be expanded to compensate for dropouts ov er the short study 
period. To maximize study efficiency and resource utilization these subjects 
will not be enrolled unless necessary.  
 
 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 12 of 43 
Protocol Template Effective: 07 JAN 2015  1 BACKGROUND  
Here, we propose a Phase II DBRCT, delayed start protocol, to evaluate the effect 
of bazedoxifene 40mg vs. placebo on promoting remyelination in women with multiple 
sclerosis (MS), as measured by Visual Evoked Potentials.  
 
Multiple sclerosis (MS) is the most prevalent chronic, non -traumatic neurological 
disorder among young adults; MS affects approximately 400 ,000 people in the United 
States and 2.1 million people around the world1.  There is no single diagnostic test for 
MS; diagnoses are made on the recognition of clinical disease patterns and the exclusion 
of alternatives.2 3  Most notably, patients are required to exhibit the spatiotemporal 
dissemination of lesions, meaning that evidence of  prior demyelinating injury must be 
present at the time of diagnosis.  The myelin sheath is an integral acc essory to functioning 
nerve fibers and provides multiple layers of concentric membrane to axons, which serves 
to increase conduction velocity and reduce energetic cost of action potentials.4  Myelin 
loss in MS res ults in disruption of the nerve signal, axonal damage, and ultimately 
neurodegeneration. To effectively prevent the downstream effects of myelin injury, novel 
approaches to promote repair will be required.  
There is a strong preclinical (including EAE)7 and epidemiologic rationale for 
investigating the remyelinating potential of estrogenic compounds, including evidence of 
endogenous (puberty, postpartum periods)8 and exogenous hormonal influences on MS 
risk9-14 and course.15,16 MS affects 3 times more women than men, and disease course in 
women appears overall l ess aggressive (on MRI, fewer T2 -hyperintense demyelinated 
lesions develop into axonal destruction visualized as hypointense T1 “black holes ”8,17).  PI 
Dr. Bove has shown that the 10% of MS women with post -menopausal onset of symptoms 
do not appear to be “protected ” from progression typical of their male c ounterpart s.18 
Further, she has shown that MS disease severity may worsen with ovarian aging.19,20 This 
age-related decline in gonadal steroids might represent a sex-specific  influence21 on age -
related disability progression,22 and on decreased CNS resilience —including  through 
remyelination —in the face of neuroinflammatory injury.  
Selective Estrogen Receptor Modulators ( SERMs ) provide more tissue -selective, full 
or partial agonism or antagonism of estrogen receptors (ER α and ERβ).25 It is widely 
believed that modulation of ER α and/or ER β induce s neuroprotection through 
remyelination.26 Supportive ob servations include the classic SERM tamoxifen leading to 
decreased severity of EAE symptoms and of demyelination,27 and that the potent, 
selective ER β agonist indazole -chloride (Ind -Cl) induces corpus callosum remyelination  
in the cuprizone -induced demyelination mouse model of MS.28 However , the SERM 
compounds currently examined, such as tamoxifen, have significant tolerability 
limitations (e.g. hot flashes), which limit their clinical application.29 In contrast, m ultiple 
other agents within this class have demonstrated pharmaceutical indications (osteoporosis, 
cancer prevention) and are more tolerable. Bazedoxifene (BZA) is a SERM recently FDA -
approved in combination with conjugated estrogens (CEs) as Duavee. BZA o ffsets 
estrogenic stimulation of endometrial and breast tissue, and CE 0.45mg/BZA 20mg is 
approved for menopausal hot flash relief and osteoporosis prevention, with a favorable 
tolerability and safety profile.25,30 In the brain, limited data suggest that BZA may 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 13 of 43 
Protocol Template Effective: 07 JAN 2015  counteract inf lammation under neurodegenerative conditions by targeting the production 
and release of pro -inflammatory molecules by glial cells.31-33 In a male rat model of 
transient focal cerebral ischemia, BZA exerted neuroprotective actions mainly in the 
cortical region, and estradiol at the subcortical level.34 Further, our pre -published work 
presented at this year ’s joint Americas —Europea n Committee for Treatment and Research 
in Multiple Sclerosis (ACTRIMS —ECTRIMS) conference in Paris, demonstrates that 
BZA enhances OPC differentiation in vitro and in vivo  and promotes functional 
remyelination (Bove  et al., ECTRIMS 2017).  
To date, the  clinical  remyelinating effects of BZA  are unknown.  
 
1.1 Overview of Non -Clinical Studies  
Screening for small molecules or biologicals that promote remyelination represents a 
promising avenue for the identification and development of reparative treatments for MS,23 but a 
significant hurdle for the rational advancement of compounds identified in screens remains the 
functional confirmation of myelin repair . Recent technical advances with screening platforms 
provide us with this unique opportunity to provide insight into the cell autonomous mechanisms 
for remyelination and address this unmet need in MS.  
SERMs have been identified as compounds capable of pro moting oligodendrocyte 
differentiation using several recent unbiased screens for remyelination ,24 including BIMA  (Binary 
Indicant for myelination using Micropillar Arrays), a functional high -throughput screen developed 
by the Chan Laboratory at UCSF.1 BIMA involves freestanding micropillar arrays of compressed 
silica around which myelin rings of membrane wrapping by oligodendroglia can be visualized in 
cross -section. These micropillars are placed in 96 - and 384 -well formats, testing therapeutic 
compounds ’ direct influences on oligodendroglia without indirect effects from neurons.  
Using this high throughput  screen,  BZA, was identified as a bioactive compound with 
strong remyelinating potential ( platform presentation, AAN 2017 Annual Meeting ).  Our pre -
published work validate d this finding in vitro and in vivo ; OPCs were derived from WT P7 rat 
pups using prev iously validated methodology (Mei et al., 2014), cultured in isolation, and treated 
with increasing concentrations (5 -500nM) of BZA for 48 hours.  At all concentrations (5nM to 
500nM) BZA significantly enhanced OPC differentiation and subsequent myelinatio n (platform 
presentation, AAN 2017 Annual Meeting [44]).  Following a lysolecithin induced toxic, focal 
demyelinating injury to the corpus collosum of 8 -week old adult mice, daily BZA delivered via 
oral gavage resulted in enhanced differentiation and an in creased number of oligodendrocytes in 
the lesion area when compared to controls. Given subsequent in vitro analysis of BZA ’s 
differentiation effect on OPCs isolated from ER  and ER null mice (not shown), which revealed 
a remyelinating mechanism that is in dependent of either ER, we performed the same in vivo  
analysis on ER -ER double knockout mice.  Comparable OPC differentiation and remyelination 
following focal demyelination confirmed that the potent reparative effects of BZA is maintained in 
the absence of ERs.  
1.2 Overview of Clinical Studies  
Remyelination. Recently published w ork from the collaborating Chan and Green Labs at UCSF, 
provides strong support for the BIMA screening method ’s ability to identify remyelinating 
compounds with strong translational potential.  Clemastine , a first -generation antihistamine , which 
is known t o readily cross the blood -brain -barrier and has been available as an ‘over the counter ’ in 
the U.S. since 1992, was identified using this screen and subsequently tested in a clinical trial 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 14 of 43 
Protocol Template Effective: 07 JAN 2015  assessing it ’s remyelinating potential in patients with MS.  This t rial ([STUDY_ID_REMOVED]) used VEP 
latency, a well -validated measure of remyelination, to gauge Clemastine ’s therapeutic efficacy  
over the course of the trial period.  To date, this remains the only randomized controlled trial to 
document efficacy of a remyelinating drug for chronic demyelinating inju ry in MS (Green et al., 
2017).  These findings support the investigation of compounds with high translational potential 
that have b een identified in BIMA screens.    
 
Bazedoxifene in clinical trials.  The recent FDA  approval of Duavee (BZA + conjugated estrogens) 
in the U.S  was largely dependent on safety and efficacy data obtained from the Selective 
estrogens, Menopause, And Response to Therapy (SMART) trials.  The first SMART trial, 
SMART -1, included 3,397 s ubjects who took at least one dose of the study drug ; of this group, 
840 participants received  the same  daily  dose of BZA (40 mg) as is outlined in this protocol.  At 
the end of the 2 -year study, the incidence of adverse events did not differ significantly  when 
compared to placebo, nor were significant differences observed between  the 20 mg and 40 mg 
BZA groups (Pickar  et al., 2009).  Subsequent SMART trials underscore the safety of BZA in 
humans but do not include 40 mg treatment groups, as 20 mg was determined to be the lowest 
effective dose.   
The approval of Conbriza (BZA) in the E.U. and Viviant (BZA) in Asia are a lso supported by 
several large -scale Phase I -III clinical trials documenting safety and efficacy.  In a 3 -year, 
randomized, placebo -, and active -controlled clinical trial assessing the efficacy of BZA in 
reducing vertebral fracture risk in postmenopausal w omen with osteoporosis, more than 3,750 
women took daily BZA, 1,872 of them at a daily dose of 40 mg.  BZA was well tolerated across 
all treatment doses over the 3 -year period of therapy and was shown to be effective in reducing 
risk of vertebral fracture,  increasing BMD of the hip and spine, and reducing bone turnover 
(Silverman et al., 2008).  Multiple other studies, albeit slightly smaller in scale, include treatment 
groups where patients received daily 40 mg BZA (Itabashi et al., 2011; Miller et al., 20 08; Ronkin 
et al., 2005) and exhibit a favorable safety and tolerability profile.   
 
2 STUDY RATIONALE  
BZA  is an approved medication  in the EU and Japan  (Conbriza and Vivant, respectively)  for the 
treatment of postmenopausal osteoporosis in women at increase d risk of fract ure.  Multiple 
longitudinal, multicenter Phase I -III trials have unequivocally supported the use of BZA in human 
populations matching our inclusion criteria for age and sex  (Itabashi et al., 2011; Miller et al., 
2008; Pickar et al., 2009; Ro nkin et al., 2005; Silverman et al., 2008).   We are confident in these 
safety data, which underscore the minimal assumption of risk, and believe the benefit to individual 
patients with MS —and the scientific community as a whole —to be far greater than the b urden of 
reasonably occurring treatment emergent adverse reactions.  
2.1 Risk / Benefit Assessment  
The potential benefit resulting from participation in this study is immense —both for the individual 
and the scientific community.  If our preclinical findings, indicating BZA ’s therapeutic potential 
for remyelination, are upheld in patients with MS, it will represent a significant step towards 
fulfilling the long unmet need for reparative treatments.   These potential benefits outweigh the 
minimal risk a ssumed in participation in this study.   
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 15 of 43 
Protocol Template Effective: 07 JAN 2015  3 STUDY OBJECTIVES  
3.1 Primary Objective  
The primary objective is to evaluate the efficacy of BZA relative to placebo for reducing P100 
latencies on full field transient pattern reversal visual evoked potentials at 90 day s in a double -
blinded trial (1st 90 days in Group A versus 1st 90 days of Group B.)  
3.2 Secondary Objectives  
● The first key secondary objective is to assess whether latency delay at 180 days 
decreases to a greater extent in Group A (exposed to BZA for 90 days during both Stage 1 
and Stage 2) when compared to Group B (exposed to placebo during Stage 1 and BZA for 
only 90 days during Stage 2).  
● The second key secondary objective is to demonstrate the tolerability of BZA in this 
population. This will include  special focus with regards to fatigue as this is a major 
symptom for patients suffering from multiple sclerosis.  
● The third key secondary objective is to document the safety of BZA in this population 
of patients.  
● The fourth key secondary objective of t his study is to help assess which secondary and 
tertiary outcomes are likely to be informative for future remyelinating trials in multiple 
sclerosis.  
Additional Secondary Objectives:  
● To evaluate the efficacy of BZA relative to placebo in increasing magne tization 
transfer ratios derived from magnetic resonance imaging of the brain during the 
period of exposure to active treatment.  
● To evaluate the efficacy of BZA relative to placebo in reducing latency delay on 
multifocal visual evoked potentials during t he period of exposure to active 
medication.  
● To evaluate the efficacy of BZA relative to placebo at reducing radial 
diffusivity derived from diffusion tensor imaging as assessed by magnetic 
resonance imaging during the period of exposure to active medicat ion. 
● To evaluate the efficacy of BZA in reducing the EDSS score at the end of Stage 
1 (Group A exposed to BZA for 90 days, Group B exposed to placebo for 90 
days), as well the efficacy of BZA in reducing EDSS at the end of Stage 2 (after 
180 days of BZA in Group A and 90 days of placebo + 90 days of BZA in Group 
B).   
● To evaluate the efficacy of BZA relative to placebo in improving Symbol Digit 
Modalities Test (SDMT) performance at the end of Stage 1 and at the end of 
Stage 2.  
 
4 STUDY DESIGN  
4.1 Study Overv iew 
This is a 6 -month randomized, single center, double blinded, delayed start study in 50 patients 
with relapsing remitting multiple sclerosis and identified injury to the anterior visual pathway.  
 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 16 of 43 
Protocol Template Effective: 07 JAN 2015  Patients will be randomized 1:1 into two groups: Group A and Group B. Group A will receive 180 
days of Bazedoxifene while Group B will receive 90 days of placebo followed by 90 days of 
Bazedoxifene. Patients will receive two fixed oral tablet s of 20mg Bazedoxifene  (Conbriza)  daily  
(to be taken at the same time) .  Patients will be permitted to remain on their standard disease 
modifying treatment duri ng the course of the study.  
 
Screening data will be reviewed to determine subject eligibility.  Subjects who meet all 
inclusion criteria and none of the exclusion criteria will be entered into the study  
5 CRITERIA FOR EVALUAT ION  
5.1 Primary Efficacy Endpoint  
Visual evoked potentials  (VEPs) are cortically generated electrical potentials recorded over the 
scalp in response to a visual stimulus. After stimulation, a transient, cortically generated response 
is tied to the relevant stimulus (the transient VEP) and co nsists of a series of potentials that are 
alternately positive and negative in polarity.  They are labeled on the basis of their polarity and 
latency. In most individuals, the first response of the full - field pattern -reversal VEP recorded mid -
occipitally is a negative deflection termed the N75. However, given lack of consistency of both the 
presence and latency of the N75, by convention full -field VEPs usually are assessed by evaluating 
the first major positive deflection that occurs in normal individuals at around 100 msec and is 
therefore designated the P100 component. Latency of the VEP is defined as the time from the 
stimulus to a pre -specified feature of the record.  
Following application of scalp leads by the technician, patients will be seated in front of a CRT 
screen.  VEPs will be performed using a single Nicolet VEP instrument under standardized 
conditions of luminance, distance and check contrast.  Check size wil l be held at 32 minutes of arc 
as calculated by the formula M = 3438*W/D (M = minutes of arc; W = width of an individual 
check; D = distance from screen in mm).  Standard recording time is approximately 25 -30 minutes 
including the time required for applica tion of the leads.  The participant will be instructed to wear 
corrective lenses if they have them. If they do not, they will be provided with a pair of trial lenses. 
The primary outcome of interest will be the P100 latency although other parameters may be  
studied at a later date in secondary analyses.  
  
5.2 Secondary Efficacy Endpoints  
5.2.1  Expanded Disability Status Scale (EDSS)  
 
EDSS Score will be determined, based on neurological examination, by a trained certified EDSS 
rater at sched uled visits according to Appendix -1 using the validated Neurostatus scoring system. 
Whenever possible, individual patients will have EDSS performed by same rater on each visit.  
The EDSS is an ordinal scale used for assessing neurological impairment of MS  based on a 
neurological examination. It consists of scores in each of seven functional systems (FS) and an 
ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 
(death due to MS)]. The FSs are the Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & 
Bladder, and Cerebral functions. The FSs and EDSS steps will be assessed in a standardized 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 17 of 43 
Protocol Template Effective: 07 JAN 2015  manner. EDSS is a widely used and accepted instrument to evaluate disability status at a given 
time and longitudinally, to as sess disability progression in clinical studies in MS.  
Disability progression based on the EDSS is defined as an increase from baseline of 1 point (in 
patients with a baseline EDSS score of 3.0 to 5.0 inclusive) or of 0.5 point (in patients with a 
baseline  EDSS score of 5.5 to 6.5 inclusive). To confirm that the progression is sustained, this 
increase should, at a minimum, be present at a visit at least 3 months later (for 3 -month confirmed 
disability progression) with any intervening EDSS values also meeti ng the criteria for change.  
Analysis of disability progression based on the EDSS  score will include variables such as:  
• Time to 3 -month confirmed disability progression  
• Proportion of patients free of a 3 -month confirmed disability progression  
5.2.2  Magneti c Resonance Imaging (MRI)  
All patients will undergo MRI scanning of the brain according to the schedule in Appendix -1. 
MRI evaluation will include, but is not limited to:  
Sequences:  
• Magnetization Transfer Ratio (5 minutes)  
• Radial diffusi vity on Diffusion T ensor Imaging (9 minutes)  
• T1, FLAIR (10 minutes)  
• 3D T2 star (10 minutes)  
• Number of new/ enlarging T2 hyperintense lesions  
• Total volume of T2 lesions  
• Volume of T 1 hypointense lesions  
• Change in brain volume  
All images will be obtained on a Siemens Skyra 3T MRI in th e Sandler Neurosciences Building . 
All scans will be performed by a trained MRI technician using protocols previously defined within 
the lab (specific MR settings to be defined elsewhere).  
Each MRI scan performed for the study, both scheduled and unscheduled (e.g. ordered by the 
investigator for safety or differential diagnosis), will be reviewed by a neuroradiologist and the 
primary treating physician must be contacted in case of unexpected findings  (not consistent with 
optic neuritis) detected on the MRI scan for safety actions and Adverse Event reporting.  
During the study each scan performed, both scheduled and unscheduled, will be assessed by the 
blinded trained physician from the NICMSMRI team.  Upon acquisition the MRI will be evaluated 
for quality, completeness, and adherence to the manual. Confirmation of MRI quality or a 
description of the quality problems, if detected, will be communicated to the investigators. If scan 
is incomplete or incorr ectly performed, the study center will be asked to repeat it as soon as 
possible. After completion of the quality check, all scans will be analyzed according to a 
standardized procedure.  
Scanning:  
All sequences will be performed according to lab specificat ions.  
MRI scans will include MTR, Diffusion tensor imaging, myelin water fraction, T1 -weighted 
images, T2 -weighted, Proton Density -weighted and FLAIR  images.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 18 of 43 
Protocol Template Effective: 07 JAN 2015   
5.2.3  Cognition  
5.2.3.1  Symbol Digit Modalities Test (SDMT)  
The SDMT will be assessed acco rding to the schedule in Appendix -1 (study coordinator to 
administer). The SDMT is a sensitive and specific test to assess processing speed and working 
memory which are typically affected domains in cognitively impaired MS patients. During the 
administrati on of the SDMT, only the examiner and the patient should be in the testing room. The 
examiner can be the study coordinator, independent EDSS rater or a qualified individual not 
involved in the treatment of the patients who has been instructed in the approp riate administration 
of the test. Patients are presented with a test instrument at the top of which there is a row of nine 
numbers paired with unique symbols. Below this part of the test instrument is an array of symbols 
paired with empty spaces, the patie nt’s task is to match the number for each symbol as quickly as 
possible.  The test takes approximately 5 minutes to administer. The test scoring is calculated 
based on the number of correct answers in 90 seconds.  
 
5.2.3.2   Additional cognitive tests  
Each s tudy participant will complete approximately 10 -15 minutes of cognitive testing as part of 
three separate  study visits (baseline visit, 3 -month visit, 6 -month visit). The cognitive measures 
will be administered by a trained study research assistant  at the UCSF Multiple Sclerosis Center. 
In addition to the SDMT, participants will complete the California Verbal Learning Test -II 
(CVLT -II), an assessment of verbal learning and memory with robust normative data in both 
healthy and MS populations. This task invol ves the immediate recall of a list of 16 nouns read 
aloud by the evaluator at one -second intervals.  
 
5.2.4  High C ontrast / Low Contr ast Visual Acuity (LCVA)  
Visual acuity will be assessed acco rding to the schedule in Appendix -1. Disturbances in visual 
function are common in patients with optic neuritis but these impairments are often not  readily 
apparent on commonly used high -contrast acuity tests. The use of low -contrast visual acuity charts 
has therefore gained validity in the assessment of visual acuity  in patients with optic neuritis. Low 
contrast Sloan letter charts provide a practical, quantitative, and standardized assessment of visual 
function. Each chart consists of rows of gray letters, decreasing in size from the top to the bottom 
row, on a white  background. A complete set consists of 7 charts, each with a different level of 
contrast ranging from 100% (normal vision chart) to 0.6%. For this study only two charts will be 
used, the 100%  (normal vision chart) and 2.5% contrast charts.  
When these charts are being rated it is important that standardized conditions are used (e.g. 
distance from the chart, lighting conditions). For high contrast testing, participants will be seated 4 
meters from the chart. For low contrast testing, participants will be  seated 2 meters from the chart. 
Letter scores indicate the number of letters identified correctly, each chart is scored separately. In 
both cases, testing will be conducted in a low -luminance setting.  
Low-contrast letter acuity testing with Sloan charts i s easy to administer and has been shown to 
have high inter -rater reliability both in patients with optic neuritis and in healthy volunteers. The 
participant  will be instructed to wear corrective lenses if they have them. If they do not, they will 
be provid ed with a pair of trial lenses.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 19 of 43 
Protocol Template Effective: 07 JAN 2015  To ensure consistency amongst raters and between sites, a standard prompt will be utilized for test 
administration. The administrator will ask the participant to begin at the top line of the chart, 
reading each line complete ly and down as many lines as possible. When the  
participant finishes reading the chart, they will be prompted by the tester one time: “Please give 
the next line your best attempt. ” The tester may continue to encourage the participant following the 
successf ul (greater than or equal to 4/5 letters correct) completion of each line until the participant 
can read no further.  
 
5.2.5  Optical Coherence Tomogr aphy (OCT)  
OCT will be assessed according to the schedule in  Appendix -1. Optical Coherence  Tomography 
(OCT)  is a noninvasive, noncontact, trans -pupillary imaging technology which can depict retinal 
structures in vivo with high resolution cross -section images of the retina (axial resolution of 3 - 5 
microns). Cross -sectional images of the retina are produced usin g the optical backscattering of 
light in a fashion analogous to B -scan ultrasonography.  Whereas ultrasound produces images from 
backscattered sound "echoes," OCT uses infrared light waves that reflect off the internal 
microstructure within the biological  tissues. The frequencies and bandwidths of infrared light are 
orders of magnitude higher than medical ultrasound signals -- resulting in greatly increased image 
resolution  approximately 8 -25 times greater than any existing modality. In addition, the anatomi c 
layers within the retina can be differentiated and retinal thickness can be measured.  
Infrared light is delivered to the imaging site through a single optical fiber only .006" diameter 
(about the size of the period in this sentence). The imaging guide wi re contains a complete lens 
assembly to perform a variety of imaging functions. Guide wire can be deployed independently or 
integrated into existing therapeutic or imaging catheters.  
While standard electronic techniques are adequate for processing ultrason ic echoes that travel at 
the speed of sound, interferometric techniques are required to extract the  reflected optical signals 
from the infrared light used in OCT. The output, measured by an interferometer, is computer 
processed to produce high -resolution, real time, cross sectional or 3 -dimensional images of the 
tissue. This powerful technology provides in situ images of tissues at near histological resolution 
without need for excision or processing of the specimen.  
Image scanning will be performed on a Heidelberg Spectralis Spectral Domain OCT  instrument. 
Scanning protocols will include peripapillary B scan and 19 B scan Macular raster scan with target 
ART of 100 and 50 respectively. Quality targets will be 25 for al l studies and only studies with Q> 
20 will be analyzed.  
 
5.2.6  Health Status Q uestionnair e (SF -36) 
 
For this study, a Health Status Questionnaire will be administered to patients at the three time-
points indicated in Appendix -1. The questionnaire falls und er the comprehensive Multiple 
Sclerosis Quality of Life Inventory (MSQLI), which was developed by The Consortium for 
Multiple Sclerosis Centers Health Sciences Research Subcommittee as a comprehensive outcomes 
assessment battery (Fisher et al, 1999), and i t will allow us to monitor the participants ’ quality of 
life with regard to their health.  
The Short Form -36 (SF -36) was derived from the General Health Survey of the Medical 
Outcomes Study in 1988. As cited by the Multiple Sclerosis Society, it is one of the most widely 
used generic measures of health -related quality of life and ha s been shown to discriminate between 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 20 of 43 
Protocol Template Effective: 07 JAN 2015  subjects with different chronic conditions and between subjects with different severity levels of 
the same disease. The SF -36 has also demons trated sensitivity to significant treatment effects in a 
variety of patient populations.  
This tool addresses health issues that are relevant to MS  patients from the patient's perspective. 
The SF -36 generates two summary scores based on 8 subscales. The two  scores arrived at are the 
physical component summary and the mental component summary.  
 
5.2.7  Cone Contr ast testing  
Rabin cone contrast testing will be performed at the visits indicated in Appendix 1 . The test will 
be performed using an Innova Provideo CCT. Cone sensitivity threshold testing is used to 
accurately detect shifts the may indicate the onset of eye disease. The participant will be seated so 
that their eyes are approximately 2 meters from the center of the monitor. They will be instructed 
to wear corrective lenses if they have them. If they do not, they will be  provided with a pair of trial 
lenses. The partici pant will be instructed to choose the letter that they see on the screen using a 
wireless computer mouse. Each eye will be tested individually.  
The test presents colors that use only one of your three cones types and shows the color 
progressively fainter t o individually score how the cones are functioning. Using a combination of 
color and contrast, the Rabin Cone Contrast test is a quantifiable measure of color vision, allowing 
detection of both hereditary and acquired color vision loss.  
Cone contrast testi ng will be used to assess whether BZA  versus placebo has any effect on 
preservation of color sensitivity.  
 
 
5.3 Safety Evaluations  
5.3.1 Physical Examination  
A complete physical examination will be performed by blinded clinician at the visits indicated in 
Appe ndix-1 and will include assessment of skin, head and neck, lymph nodes, heart, lungs, 
abdomen, back, neurological function, and comments on general appearance. All significant 
findings that are present prior to signing informed consent must be reported on the relevant 
medical history/ current medical conditions eCRF. Significant findings made after signing the 
informed consent and being randomized meets the definition of an Adverse Event and must be 
recorded on the Adverse Even t case report form through UCS F’s clinical database, REDCap.  
5.3.2 Vital Signs  
Vital signs will include height, sitting pulse rate, sitting systolic and diastolic blood pressure and 
body temperature which will be assessed at the visits indicated in Appendix -1. 
Clinically notified vital signs are defined in Appendix 1.  
5.3.3 Height and Weight  
Height will be assessed at the screening  visit in centimeters/ inches.  
Weight will be assessed in kilograms at the visits indicated in Appendix -1. 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 21 of 43 
Protocol Template Effective: 07 JAN 2015  Body weight in indoor clothing, but w ithout shoes will be measured. Participants should be asked 
to remove any items from their pockets and remove any outside clothing such as scarves, jackets, 
gloves, etc.  
5.3.4 Ophthalmologic Examination  
Patients will undergo screening ophthalmologic exam t o include assessment for any undiagnosed 
ophthalmologic disease that could impact assessments including but not limited  to dilated  
examination  of the fundus  and macula  by study  investigator. This evaluation will include an eye 
history, visual acuity measur ements and dilated ophthalmoscopy at the screening visit.  
Patients with a history of, or active uveitis or a history of macular edema will require special 
attention.  
In addition to visual acuity assessments and dilated ophthalmoscopy, measurement of retinal 
thickness  by OCT and measurement of VEP  latency will be  conducted at visits  as indicated in 
Appendix -1. The PI will complete  an examination of worksheet which will then be transcribed to 
an ophthalmologic examination eCRF.  
5.3.5 Fati gue Assessment   
To ensure patient safety in daily activities, we will conduct a fatigue assessment at each of the 
visits indicated in Appendix -1, in order to monitor the degree of self -reported fatigue experienced.  
The Modifie d Fatigue Impact Scale (MFIS)  is a 21 -item fatigue scale that measures the physical, 
cognitive, and psychosocial aspects of fatigue.  
 
 
5.3.6 Other Assessments  
MS is associated with a variable combination of symptoms, including sensory loss, imbalance, 
mobility loss, bladder and bowel dysfunction, cognitive dysfunction, spasticity, pain, and sexual 
dysfunction. Measurements of these wide -ranging  effects of MS  on the lives of patients  is beyond 
the scope  of the  clinician -reported endpoints  commonly used to evaluate therapeutic effe ctiveness 
in MS  studies. Patient -reported outcome (PRO) measures provide an empirical assessment from 
the patient s perspective of the benefits of treatment that cannot be gained from Magnetic 
Resonance Imaging (MRI), Expanded Disability Status  Score  (EDSS ), or Optical Coherence  
Tomography (OCT).   
5.3.7 Adverse  Event Reporting  Plan  
This study is investigator -sponsored and does  not involve  any outside  sponsoring institution to 
which adverse events should be reported. Serious Adverse Events (SAEs) or unanticipated adverse 
events, therefore, will be reported internally to the UC  San Francisco Committee on Human 
Research within 10 working days of the event s occurrence according  to requirements  outlined  in 
the CHR’s reporting  guidelines.  
All adverse even ts during this study will be recorded in real time in UCSF ’s HIPAA approved 
clinical database, REDCap.  Recording such events in the same database each paten ’s trial -based 
visit records will allow for more efficient tracking and monitoring of all adverse e vents within the 
study.   
In addition, an inventory of adverse events will be obtained at each visit.   
 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 22 of 43 
Protocol Template Effective: 07 JAN 2015  6 SUBJECT SELECTION  
6.1 Study Population  
Subjects with a clinically definite diagnosis of MS—according to the 2017 revised McDonald 
Criteria (Thompson et al., 2017) —who meet the inclusion and exclusion criteria will be eligible 
for participation in this study.   
6.2 Inclusion Criteria  
1. Women aged 45 -65 or 40+ post -menopausal.  
2. Documentation of a clinically definite diagnosis of  relapsing -remitting  MS  
3. Written informed consent (and assent when applicable) obtained from subject or 
subject’s legal representative and ability for subject to comply with the requirements of 
the study.  
4. Latency delay > 118 milliseconds on baseline full -field transient pattern  reversal VEP in 
at least one eye (electrophysiological evidence of demyelination)  
5. RNFL > 70 microns on SD -OCT in the same eye meeting criteria for latency delay 
(sufficient axons)  
6. Stable immunomodulatory therapy – no switch or planned switch in > 6 months  and no 
change in  doses in 30 days prior to screening  
7. Use of contraceptive method with ≤1% failure rate  during period of trial if 
premenopausal   
8. Understand and sign informed consent.  
9. EDSS 0 -6.0 (inclusive)  
 
6.3 Exclusion Criteria  
1. Multiple Sclerosis disease duration > 25 years  
2. Optic neuritis in prior 6 months  
3. Known optic neuritis in involved eye ≥ 10 years ago  
4. Major ophthalmologic disease/Concomitant ophthalmologic disorders (e.g. diabetes, 
macular degeneration, glaucoma, severe myopia, etc.).  
5. Myopi a > -7 Diopters (severe myopia)  
6. Disc hemorrhages in qualifying eye  
7. No light perception in qualifying eye  
8. Simultaneous bilateral optic neuritis  
9. Cotton wool spots in qualifying eye  
10. Macular star in qualifying eye  
11. History of significant cardiac conduction bl ock  
12. History of cancer  (except non -melanoma skin cancer)  
13. Suicidal ideation or behavior in 6 months prior to baseline  
14. Pregnancy, breastfeeding, or planning to become pregnant  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 23 of 43 
Protocol Template Effective: 07 JAN 2015  15. Included with other study protocol simultaneously without prior approval  
16. Concomita nt or prior use of any other putative remyelinating therapy as determined by 
investigator , including but not limited to Clemastine, Duavee, and Tamoxifen.   
17. Serum creatinine > 1.5mg/dL; AST, ALT, or alkaline phosphatase > 2 times the upper 
limit of normal   
18. History of drug or alcohol abuse within the past year  
19. Untreated B12 deficiency (as determined by B12 serological assessments and metabolites 
including methylmalonic acid [MMA] and homocysteine) or untreated hypothyroidism   
20. Clinically significant cardiac,  metabolic, hematologic, hepatic, immunologic, urologic, 
endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal or other 
major diseases that in the PI ’s judgement may affect interpretation of study results or 
patient safety.  
21. History of or presence of clinically significant medical illness or laboratory abnormality 
that, in the opinion of the investigator would preclude participation in the study.   
22. Patients whose lack of mobility exposes them to an increased risk of venous 
thrombo embolism  
23. Patients with undiagnosed uterine bleeding  
24. Patients with unknown, suspected or past history of breast cancer  
25. Patients with known or suspected estrogen -dependent neoplasia  
26. Patients with active or a past history of venous thromboembolism  
27. Patients with active or a past history of arterial thromboembolism  
28. Patients with known protein C, protein S, or antithrombin deficiency or other 
known thrombophilic disorders  
29. Patients with hypersensitivity (angioedema, anaphylaxis) to estro gens, 
bazedoxifene, or any ingredients  
30. Patients with known hepatic impairment or disease  
 
7 CONCURRENT MEDICATIO NS 
All subjects should be maintained on the same medications throughout the entire study period, as 
medically feasible, with no introduction of ne w chronic therapies.  
7.1 Allowed Medications and Treatments  
Standard therapy for MS is allowed except for treatments noted in the exc lusion criteria described 
above.   
8 STUDY TREATMENTS  
8.1 Method of Assigning Subjects to Treatment Groups  
Up to 50 eligible patients will be randomly assigned to ‘Early ’ or ‘Delayed Start ’ treatment groups 
in a 1:1 ratio using a SAS -based computer -generated randomization scheme developed by the 
study data management provider. The CTSI statistician advising the PI will  complete a 
randomization worksheet.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 24 of 43 
Protocol Template Effective: 07 JAN 2015  8.2 Blinding  
Due to the objectives of the study, the identity of test and control treatments will not be known to 
investigators, research staff, or patients.  The following study procedures will be in place to ensure 
double -blind administration of study treatments.   
- Access to the randomization code will be strictly controlled.   
- The CTSI statistician advising the PI will perform the randomization/blinding chart 
and provide this to the Compounding Pharmacy. They will perform  interim safety 
analysis without unblinding the study, and will only unblind the study to the 
investigators at the end of study.  
- Packaging and labeling of test and control treatments will be identical to maintain the 
blind.  
- Packaging and labeling will be  done by pharmacy personnel who are not involved in 
analysis of study data.  
The study blind will be broken on completion of the clinical study and after the study database has 
been locked. The investigators will be given the randomization worksheet from th e CTSI 
statistician after the last participant has completed their study.  
During the study, the blind may be broken only in emergencies when knowledge of the patient’s 
treatment group is necessary for further patient management. When possible, the Investig ator 
should discuss the emergency with Dr. Riley Bove  prior to unblinding.   
8.3 Formulation of Test and Control Products  
8.3.1 Formulation of Test Product  
BZA is a third -generation selective estrogen receptor modulator (SERM). It is an immediate 
release, film -coated capsule shaped tablet. Tablets contain 20 mg of bazedoxifene expressed as 
free base. The tablets are supplied from Pfizer in blister packaging  (commercially available 
Conbriza) and delivered to the compounding pharmacy unopened .    
For blinding, it will encapsulated in a gelatin capsule and fill remaining space with 
microcrystalline cellulose, by Koshland Compounding Pharmacy (Dr. Peter Koshland ) at: 
 
Koshland Pharm  
301 Folsom Street, Suite B  
San Francisco, CA, 94105  
(p) 415.344.0600  
(f) 415.344.0607  
 
Table 1: Formulation and Measured pH of BZA  and Placebo  
 2x (BZA , 20 mg ) Placebo  
Active Ingredient, mg/mL  Bazedoxifene acetate   
Other ingredient, mg/mL  Lactose, microcrystalline 
cellulose, pre -gelatinised starch Microcrystalline cellulose  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 25 of 43 
Protocol Template Effective: 07 JAN 2015  (maize), sodiu m starch glycolate, 
sodium lauryl sulfate, colloidal 
anhydrous silica, magnesium 
stearate, ascorbic acid, 
hypromellose, titanium dioxide 
(E171) and macrogol 400.  
 
8.3.2 Formulation of Control Product  
Placebo is: Microcrystalline cellulose, encapsulated into a gelatin capsule, taken daily . 
8.3.3 Packaging and Labeling  
Both the drug and the placebo will be single use daily capsules  (2/day)  packaged into monthly 
bottles . Each carton (kit) of study drug will be labeled with the required FDA warning statement, 
the protocol number, a treatment number, the name of the sponsors, and directions for patient use 
and storage.  
8.4 Supply of Study Drug at the Site  
The Sponsor ( Dr. Riley Bove ) will ship Study Drug to the investigational pharmacy.  The initial 
study drug shipment will be shipped after site activation (i.e., all requ ired regulatory 
documentation has been received by the Sponsor and a contract has been executed). Subsequent 
study drug shipments will be made as needed, per pace of enrollment and drug expiration 
requirements . 
The randomization and blinding chart will be provided by CTSI statistician to the pharmacy 
personnel. Koshland Compounding Pharmacy  will then ship the study drug to the PI, and the 
research team (PI or research coordinator) will give the package  to participants at research visits 
(quantity of study d rug determined by expiry of investigational product batch) .  
8.4.1 Dosage/Dosage Regimen  
The medication (BZA or placebo) will be taken once daily, in the morning, for the duration of the 
study ( stage 1 = 3 months, stage 2 = 3 months).   
8.4.2 Dispensing  
The Koshland  Compounding pharmacy will ship the drugs to study personnel, who will then give 
the samples to the study participants at each research visit.  Should the available batch of study 
drug carry an expiration fewer than 3 months from the time of dispensing, study staff may provide 
a 1-2month supply at the time of the visit and then re -supply with newer stock via mail or in -
person delivery.  
8.4.3 Administration Instructions  
Patients will take 2 capsules  orally once a day.  
8.5 Supply of Study Drug at the Si te 
Study personnel will receive the Study Drug/placebo shipment from the Koshland  Compounding 
Pharmacy and maintain it under locked conditions in the Sandler Neurosciences Center. Subjects 
will be randomized and provided the study drug on the same day.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 26 of 43 
Protocol Template Effective: 07 JAN 2015  8.5.1 Storage  
Study drug should be stored by the study site at controlled room temperature, 15 to 30ºC (59 to 
86ºF). Subjects will be instructed to store the medication in bottles  at room temperature according 
to the instructions outlined on the Drug Administration  Instructions.  
8.6 Study Drug Accountability  
An accurate and current accounting of the dispensing and return of study drug for each subject will 
be maintained on an ongoing basis by a member of the study site staff.  The number of study drug 
dispensed and retu rned by the subject will be recorded on the Investigational Drug Accountability 
Record.  The study monitor will verify these documents throughout the course of the study.  
8.7 Measures of Treatment Compliance  
Subjects will be asked to keep a patient diary notin g the day and date they take their study drug 
and any adverse events. They will be asked to bring their patient diary to each study visit along 
with all used and unused study drug containers.  
9 STUDY PROCEDURES AND  GUIDELINES  
A Schedule of Events representin g the required testing procedures to be performed for the duration 
of the study is diagrammed in Appendix 1.  
Prior to conducting any study -related activities, written informed consent and the Health Insurance 
Portability and Accountability Act  (HIPAA) authorization must be signed and dated by the 
subject .  If appropriate, assent must also be obtained prior to conducting any study -related 
activities.  
9.1 Clinical Assessments  
9.1.1 Concomitant Medications  
All concomitant medication and concurrent therapies will be documented at Baseline/Screening 
and at Study  visits , and at early termination when applicable.  Dose, route, unit frequency of 
administration, and indication for administration and dates of medication will be captured.  
9.1.2 Demographics  
Demo graphic information (date of birth, gender, race) will be recorded at Screening.  
9.1.3 Medical History  
Relevant medical history, including history of current disease, other pertinent respiratory 
history, and information regarding underlying diseases will be rec orded at Screening . 
9.1.4 Physical Examination  
A complete physical examination will be performed by either the investigator or a sub -investigator 
who is a physician at the Screening Visit.  Qualified staff (MD, NP, RN, and PA) may complete 
the abbreviated physic al exam at all other visits.  New abnormal physical exam findings must be 
documented and will be followed by a physician or other qualified staff at the next scheduled visit.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 27 of 43 
Protocol Template Effective: 07 JAN 2015  9.1.5 Vital Signs  
Body temperature, blood pressure, pulse and respirations will be perf ormed after resting 
for 5  minutes at all Study Visits . 
9.1.6 Other Clinical Procedures  
Timed Walking Assessments:  
T25W:  The Timed 25 -foot Walk will be assessed according to the schedule in Appendix -1. The 
Timed Walk is an objective quantitative test of neurological function, and is one of three 
components of the Multiple Sclerosis Functional Composite (MSFC), a composite measure 
assessing upper extremity function, ambulation and cognitive function (Fisher et al. 1999). The 
Timed Walk is an ambulation mea surement: a walk of 25 feet (7.62 meters): time taken in 
seconds. The Timed Walk test will be administered either by the Independent EDSS Rater or by 
another qualified individual not involved in the treatment of the patients.  
6-minute walking distance: The distance subjects can walk in 6 minutes will be assessed on 3 
separate occasions as indicated in Appendix -1. The evaluating physician will use a measured 
hallway to assess the distance subject can walk at safe comfortable speed over a 6 -minute period.  
Timed up and go (TUG): The TUG test is a valuable measure of subject’s gait and postural 
stability which will be administered according to the schedule in Appendix -1.  The test requires 
that subjects start seated in an arm chair, stand up, walk 3 meters to a designated line, then return 
to their starting seated position.  As a safety precaution, the trained evaluator should maintain a 
close distance to the subject throughout the test.  
Symbol Digit Modalities Test (SDMT):  
The SDMT will be assessed according to  the sched ule in Appendix -1 (study coordinator to 
administer). The SDMT is a sensitive and specific test to assess processing speed and working 
memory which are typically affected domains in cognitively impaired MS patients. During the 
administration of th e SDMT, only the examiner and the patient should be in the testing room. The 
examiner can be the study coordinator, independent EDSS Rater or a qualified individual not 
involved in the treatment of the patients who has been instructed in the appropriate ad ministration 
of the test. Patients are presented with a test instrument at the top of which there is a row of nine 
numbers paired with unique symbols. Below this part of the test instrument is an array of symbols 
paired with empty spaces, the patient ’s tas k is to ver bally match the number for each symbol as 
quickly as possible. The test takes approximately 5 minutes to administer. The test scoring is 
calculated based on the number of correct answers in 90 seconds.  
Low Contrast Visual Acuity (LCVA):  
The LCVA will be assessed acco rding to the schedule in Appendix -1. Disturbances in visual 
function are common in patients with MS but these impairments are often not readily apparent on 
commonly used high - contrast acuity tests. The use of low -contrast visual acuity charts have 
therefore gained validity in the assessment of visual acuity in patients with MS. Low contrast 
Sloan letter charts provide a practical, quantitative, and standardized assessment of visual 
function. Each chart consists of rows of gray let ters, decreasing in size from the top to the bottom 
row, on a white background. A complete set consists of 7 charts, each with a different level of 
contrast ranging from 100% (normal vision chart) to 0.6%. For this study only two charts will be 
used, the 1 00% (normal vision chart) and 2.5% contrast charts. When these charts are being rated 
it is important that standardized conditions are used (e.g. distance from the chart, lighting 
conditions). Letter scores indicate the number of letters identified correct ly, each chart is scored 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 28 of 43 
Protocol Template Effective: 07 JAN 2015  separately. Low -contrast letter acuity testing with Sloan charts is easy to administer and has been 
shown to have high inter -rater reliability both in patients with MS and in healthy volunteers.  
Magnetic Resonance Imaging (MRI)  
A baseline MRI scan of the central nervous system (CNS) will be obtained. Both T1 and T2 -
weighted images will be obtained.  
The following parameters will be assessed using these MRI data:  
• Myelin water fraction  
• Magnetization Transfer Ratio  
• Radial diffusivity on Diffusion Tensor Imaging  
• Number of new/enl arging T2 hyperintense lesions  
• Total volume of T2 lesions,  
• Volume of un -enhancing T1 hypointense lesions,  
• Change in brain volume  
All images will be obtained on the NIC MS Scanner in the Sand ler Neurosciences Building. All 
scans will be performed by a trained MRI technician using protocols previously defined within the 
lab (specific MR settings to be defined elsewhere). Each MRI scan performed for the study, both 
scheduled and unscheduled (e.g . ordered by the investigator for safety or differential diagnosis), 
will be reviewed by a neuroradiologist. The Primary Treating Physician must be contacted in case 
of unexpected findings (not consistent with MS) detected on the MRI scan for safety action s and 
Adverse Event reporting. During the study each scan performed, both scheduled and unscheduled, 
will be assessed by the blinded trained physician from the NIC MS MRI team. Upon acquisition 
the MRI will be evaluated for quality, completeness, and adher ence to the manual. Confirmation 
of MRI quality or a description of the quality problems, if detected, will be communicated to the 
investigators. If scan is incomplete or incorrectly performed, the study center will be asked to 
repeat it as soon as possibl e. After completion of the quality check, all scans will be analyzed 
according to a standardized procedure.  
For the MRI exam, each participant will be asked a number of questions concerning his or health, 
lack of metal implants and absence of claustrophobi a. They will be asked to lie down on a narrow 
bed that will then be moved into a tunnel that is 6 feet by 2.5 feet. Each person will need to lie 
there quietly for about 1.5 hours during which time machine -like banging noises will occur. 
Earplugs will be pr ovided to reduce the sound level. Communication with the technologists 
outside will be possible at all times by a microphone and loudspeaker. If the participant wishes to 
be removed from the magnet, this will be done immediately.  
Visual Assessments  
A routi ne functional visual assessment will be made. The invest igator will examine the volunteer's 
eyes (visual acuity, pupil exam, color, motility, King Devick's test for saccades, dilating exam, 
intraoccular pressure). The patient may be asked to fill out a que stionnaire regarding their visual 
function. Then an OCT will be performed. Ocular Coherence Tomography (OCT) is a special test 
that evaluates and counts the retinal fiber layer by having the participant focus on a target.  
The entire examination will last a pproximately one hour and 15 minutes (seventy -five minutes) -- 
some patients will additionally be offered special tests that include:  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 29 of 43 
Protocol Template Effective: 07 JAN 2015  1. Full -Field visual evoked potential (ffVEP) and multifocal electroretinogram (ERG) are 
special tests that provide inform ation about optic nerve function by having the participant 
focus on a constantly changing array of checkerboard lights.  
2. Octopus 900 visual field analyzer using a Humphrey's protocol (HVF FDT) or 
Heidelberg Perimetery (HEP) visual field analyzer are spec ial automated  visual field tests 
that specifically evaluate ganglion cell function by having the participant push a button 
when they see a light.  
This additional testing will require approximately two hours (one -hundred and twenty 
minutes).  
Ophthalmologic  Examination  
Patients will undergo screening ophthalmologic exam to include assessment for any undiagnosed 
ophthalmologic disease that could impact assessments including but not limited to dilated 
examination of the fundus and macula by study investigator.  This evaluation will include an eye 
history, visual acuity measurements and dilated ophthalmoscopy at the screening visit.  
Pharmacokinetics/Lab Tests  
Participant ’s serum and PBMCs will be properly stored for later analysis (if needed).  
 
9.1.7 Adverse Events  
Information regarding occurrence of adverse events will be captured throughout the study. 
Duration (start and stop dates and times), severity/grade, outcome, treatment and relation 
to study drug will be recorded on the case report form (CRF).  
9.2 Clinic al Laboratory Measurements  
9.2.1 Hematology  
Blood will be obtained and sent to each site’s clinical hematology lab f or a complete blood count 
(hemoglobin, hematocrit, red blood cell count, white blood cell count, white blood cell 
differential, and platelet count ), and serum C -reactive protein (CRP) determinations for 
assessment of systemic evidence for infection and/or inflammation.  
9.2.2 Blood Chemistry Profile  
Blood will be obtained and sent to each site’s clinical chemistry lab for determination of serum 
sodium, pot assium, chloride, bicarbonate, random glucose, BUN, creatinine, aspartate 
aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), alkaline phosphatase, 
total bilirubin, direct bilirubin.  
 
10 EVALUATIONS BY VISIT  
10.1 Visit 1 ( Week 0) - Screening  
1. Review the study with the subject and obtain written informed consent and HIPAA 
authorization and assent, if appropriate.  
2. Assign the subject a unique screening number.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 30 of 43 
Protocol Template Effective: 07 JAN 2015  3. Record demographics data.  
4. Record medical history, including a history of MS, diagnosis d ate, and prior MS treatments, 
as well as history of optic neuritis . 
5. Record concomitant medications.  
6. Perform a complete physical examination.  
7. Perform VEP and OCT assessment s (if no record of assessment within past 6 months ) 
8. Perform and record vital signs.  
9. Perform and record results of blood pressure testing.  
10. Collect blood for clinical laboratory tests (chemistry, hematology , pregnancy test ) 
11. Initiate subject diary  
12. Schedule subject for Visit 2 in 14 days +/ -2. 
 
10.2 Visit 2 ( Baseline ) 
1. Concomitant medications review.  
2. Perform abbreviated physical examination.  
3. Assess likely side effects via clinician observation and questionnaires  
4. Perform and record vital signs.  
5. Perform neurologic & ophthalmologic exam . 
6. Perform and record visual assessments (OCT, high/low contrast vision testing, cone 
contrast, VFQ ) 
7. Perform and record cognitive & other tests  (SDMT, M FIS, EDSS , SF-36) 
8. Perform timed walking tests (T25W, TUG, 6min walking test)  
9. Perform MRI (no contrast)  
10. Randomize subject, dispense study drug  
11. Collect blood for research laboratory tests (if needed)  
 
10.3 Visit 3 ( 3-month ) 
1. Record any Adverse Experiences and/or Review subject diary for adverse experiences and 
dosing compliance.  
2. Record changes to concomit ant medications.  
3. Perform abbreviated physical examination.  
4. Assess likely side effects via clinician observation and questionnaires  
5. Perform and record vital signs.  
6. Collect blood for research laboratory tests (if needed)  
7. Perform  neurologic and  ophthalmologi c exam .  
8. Perform and record visual assessments (high/low contrast vision testing, cone contrast, 
VFQ)  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 31 of 43 
Protocol Template Effective: 07 JAN 2015  9. Perform and record cognitive & other tests (SDMT, MFIS , EDSS , SF-36) 
10. Perform timed walking tests (T25W, TUG, 6 min walking test)  
11. Perform MRI (no contrast)  
 
10.4 Visit 4 ( 6-month ) 
1. Record any Adverse Experiences and/or Review subject diary for adverse experiences and 
dosing compliance.  
2. Record changes to concomitant medications.  
3. Perform abbreviated physical examination.  
4. Assess likely side effects via clini cian observation and questionnaires  
5. Perform and record vital signs.  
6. Collect blood for research laboratory tests (if needed)  
7. Perform neurologic and ophthalmologic exam  
8. Perform and record visual assessments (OCT, high/low contrast vision testing, cone 
contrast, VFQ)  
9. Perform and record cognitive & other tests (SDMT, MFIS , EDSS , SF-36)  
10. Perform timed walking tests (T25W, TUG, 6 min walking test)  
11. Perform MRI (no contrast)  
12. Collect blood for clinical laboratory tests (chemistry, hematology)  
 
10.5 Early Withdrawal Vis it 
1. Record any Adverse Experiences and/or Review subject diary for adverse experiences and 
exclusionary medication use.  
2. Record changes to concomitant medications.  
3. Perform complete physical examination.  
4. Perform and record vital signs.  
5. Collect blood for clinical laboratory tests  (chemistry, hematology)  
11 ADVERSE EXPERIENCE R EPORTING AND DOCUMEN TATION  
11.1 Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a 
patient administered a pharmaceutical product and that  does not necessarily have a causal 
relationship with the treatment.  An AE is therefore any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom or disease temporally associated 
with the administration of an investigational product, whether or not related to that 
investigational product.  An unexpected AE is one of a type not identified in nature, 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 32 of 43 
Protocol Template Effective: 07 JAN 2015  severity, or frequency in the current Brochure or of greater severity or frequency than 
expected based on the information in the I nvestigator’s Brochure.  
The Investigator will probe, via discussion with the subject, for the occurrence of AEs 
during each subject visit and record the information in the site’s source documents.  
Adverse events will be recorded in the patient CRF.  Adver se events will be described by 
duration (start and stop dates and times), severity, outcome, treatment and relation to 
study drug, or if unrelated, the cause.  
AE Severity  
The National Cancer Institute’s Common Terminology Criteria for Adverse Events 
(CTCAE ) Version 3.0 should be used to assess and grade AE severity, including 
laboratory abnormalities judged to be clinically significant. The modified criteria can be 
found in the study manual.  If the experience is not covered in the modified criteria, the 
guidelines shown in Table 1 below should be used to grade severity.  It should be pointed 
out that the term “severe” is a measure of intensity and that a  severe AE is not necessarily 
serious.  
Table 1.  AE Severity Grading  
Severity (Toxicity Grade)  Description  
Mild (1)  Transient or mild discomfort; no limitation in activity; no medical 
intervention or therapy required. The subject may be aware of the sign 
or symptom but tolerates it reasonably well.  
Moderate (2)  Mild to moderate limitation in activity, no or minimal medical 
intervention/therapy required.  
Severe (3)  Marked limitation in activity, medical intervention/therapy required, 
hospitalizations possible.  
Life-threatening (4)  The subject is at risk of death due to the adverse experience as it 
occurred. This does not refer to an experience that hypothetically 
might have caused death if it were more s evere.  
 
AE Relationship to Study Drug  
The relationship of an AE to the study drug should be assessed using the following the 
guidelines in Table 2. 
Table 2.  AE Relationship to Study Drug  
Relationship  
to Drug  Comment  
Definitely  Previously known toxicity of agent; or an event that follows a reasonable temporal 
sequence from administration of the drug; that follows a known or expected response 
pattern to the suspected drug; that is confirmed by stopping or reducing the dosage of 
the drug; and that is not explained by any other reasonable hypothesis.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 33 of 43 
Protocol Template Effective: 07 JAN 2015  Probably  An event that follows a reasonable temporal sequence from administrat ion of the 
drug; that follows a known or expected response pattern to the suspected drug; that is 
confirmed by stopping or reducing the dosage of the drug; and that is unlikely to be 
explained by the known characteristics of the subject’s clinical state or  by other 
interventions.  
Possibly  An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to that suspected drug; but 
that could readily have been produced by a number of other factors.  
Unrelated  An event that can be determined with certainty to have no relationship to the study 
drug.  
11.2 Serious Adverse Experiences (SAE)  
An SAE is defined as any AE occurring at any dose that results in any of the following 
outcomes:  
• death  
• a life-threatening adverse experience  
• inpatient hospitalization or prolongation of existing hospitalization  
• a persistent or significant disability/incapacity  
• a congenital anomaly/birth defect  
Other important medical events may also be considered an SAE when , based on 
appropriate medical judgment, they jeopardize the subject or require intervention to 
prevent one of the outcomes listed.  
 
11.2.1  Serious Adverse Experience Reporting  
Study sites will document all SAEs that occur (whether or not related to study drug) per UCSF 
CHR Guidelines  and those outlined in 21CFR312.32 .  The collection peri od for all SAEs will 
begin after informed consent is obtained and end after procedures for the final study visit have 
been completed.  
This study is investigator -sponsored and does not involve any outside sponsoring institution to 
which adverse events shoul d be reported. Serious Adverse Events (SAEs) or unanticipated adverse 
events, therefore, will be reported to the FDA CDER (Center of Drug Evaluation and Research), 
as well as internally to the UC San Francisco Committee on Human Research  (CHR),  within 
respective reporting guidelines.  
Unexpected fatal or life -threatening suspected adverse reactions will be reported to the CDER no 
later than 7 calendar days after initial receipt of the information . UCSF CHR will be notified 
within 10 working days of the even t’s occurrence.  
Per 21 CFM 312.32(c)(1), any (1) serious, unexpected suspected adverse reactions, (2) findings 
from other clinical, animal, or in -vitro studies that suggest significant human risk, and (3) a 
clinically important increase in the rate of a se rious suspected adverse reaction will be reported to 
the CDER no later than 15 calendar days after determining that the information qualifies for 
reporting . 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 34 of 43 
Protocol Template Effective: 07 JAN 2015  All adverse events during this study will be recorded in real time in UCSF ’s HIPAA approved 
clinical database, REDCap. Recording such events in the same database as each patient ’s trial-
based visit records will allow for more efficient tracking and monitoring of all adverse events 
within the study.   
In accordance with the standar d operating procedures and policies of the local Institutional Review 
Board (IRB)/Independent Ethics Committee (IEC), the site investigator will report SAEs to the 
IRB/IEC  as described above .   
11.3 Medical Monitoring  
Dr. Jeffrey Gelfand  should be contacted dir ectly at these numbers to report medical 
concerns or questions regarding safety.  
Phone :  (415) 680-4900  
Pager  : (415) 443 -0871 
   
12 DISCONTINUATION AND REPLACEMENT OF SUBJE CTS  
12.1 Early Discontinuation of Study Drug  
A subject may be discontinued from study treatment at any time if the subject, the investigator, or 
the Sponsor feels that it is not in the subject ’s best interest to continue.  The following is a list of 
possible reas ons for study treatment discontinuatio n:  
• Subject withdrawal of consent (or assent)  
• Subject is not compliant with study procedures  
• Adverse event that in the opinion of the investigator would be in the best interest of the 
subject to discontinue study treatment  
• Protocol violation requiring disc ontinuation of study treatment  
• Lost to follow -up 
• Sponsor request for early termination of study  
• Positive pregnancy test (females)  
If a subject is withdrawn from treatment due to an adverse event, the subject will be followed and 
treated by the Investigator until the abnormal parameter or symptom has resolved or stabilized.   
All subjects who discontinue study treatment should come in  for an early discontinuation visit as 
soon as possible and then should be encouraged to complete all remaining scheduled visits and 
procedures.  
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and  without prejudice.  
Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals.  
The reason for the subject’s withdrawal from the study will be specified in the subject’s source 
documents Refer to Section 10 for early termination procedures.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 35 of 43 
Protocol Template Effective: 07 JAN 2015  12.2 Withdrawal of Subjects from the Study  
A subject may be withdrawn from the study at any time if the subject, the investigator, or the 
Sponsor feels that it is not in the subject’s best interest to continue.    
All subjects are free to  withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.  
Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals.   
The reason for the subject’s withdrawal from the s tudy will be specified in the subject’s source 
documents.   As noted above, subjects who discontinue study treatment early (i.e., they withdraw 
prior to Visit 4 ) should have an early discontinuation visit. Refer to Section 10 for early 
termination procedure s.  Subjects who withdraw after Visit 3  but prior to Visit 4  should be 
encouraged to come in for a final visit (and the procedures to be followed would include those for 
their next scheduled visit).    
12.3 Replacement of Subjects  
We plan to enroll 60 participants to consent 50.   
Subjects who withdraw from the study tre atment will not be replaced.   
Subje cts who withdraw from the study  will not be replaced.   
13 PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, investigator, or investigator  fails to adhere to 
significant protocol requirements affecting the i nclusion, exclusion, subject safety and primary 
endpoint criteria.  Protocol violations for this study include, but are not limited to, the following:  
Failure to meet inclusion/exclusion criteria  
Use of a prohibited concomitant medication  
Failure to comply  with Good Clinical Practice (GCP) guidelines will also result in a protocol 
violation. The PI will determine if a protocol violation will result in withdrawal of a subject.  
When a protocol violation occurs, it will be discussed with the investigator and a  Protocol 
Violation Form detailing the violation will be generated. This form will be signed by a Sponsor 
representative and the Investigator. A copy of the form will be filed in the site’s regulatory binder 
and in the Sponsor’s files.  
14 DATA SAFETY MONITORI NG  
Safety Data Monitoring throughout the trial: Since this trial is a single -site trial and the overseeing 
Principle Investigator  will be present throughout the trial, a Data and Safety Monitoring Board is 
not deemed necessary. The study investigator will be responsible for monitoring safety data and 
adverse events recorded in the patient file and will be responsible for reporting s uch events to the 
FDA and IRB.  
Safety assessments will be throughout patient visits to ensure patient welfare and safety in daily 
activities.  
Such assessments will include:  
- Physical Examination  
- Vital Signs   
- Height and Weight measurements  
- Pregnancy and Assessments of Fertility  
- Ophthalmologic Examination  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 36 of 43 
Protocol Template Effective: 07 JAN 2015  - Fatigue Assessment  - Health Status Questionnaire & MFIS  
- Pharmacokinetics/Blood tests to assess potential abnormal increase of liver enzymes 
and serum triglycerides  
- Lab tests to assess lev el of BZA  in patient plasma to ensure that they are not abnormal  
 
The Investigator will meet with the study staff biweekly to review safety as well as efficacy data 
collected from patient visits and assess the safety of the visits and study outcomes.  
 
Patient withdrawal from the study / Stopping rules:  
Study treatment must be discontinued for any patient if the investigator determines that continuing 
would result in a significant risk for that patient. The following conditions/events may be 
considered su fficient to support a decision about the study drug discontinuation in individual 
cases:  
- Adverse event/serious adverse event   
- Abnormal laboratory value(s) or abnormal test result(s)   
- Withdrawal of informed co nsent  
- Pregnancy   
- Use of prohibited other inves tigational medications   
- Deviations from the prescribed dose regimen for the study drug  
-  Any other protocol deviation that results in a significant risk to the patient ’s sa fety  
 
Discontinuation of the study drug must be recorded along with the patient information in 
REDCap, giving the date and primary and secondary reasons for stopping study treatment.  
The investigator must also contact the Institutional Review Board  at the study  site (University of 
California at San Francisco Multiple Sclerosis Center) to register the patient ’s discontinuation of 
randomized study drug.  
Patients may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn i f they state an intention to withdraw, fail to return for visits, or become lost 
to follow -up for any other reason.  
For patients who are lost to follow -up (i.e. those patients whose status is unclear because they fail 
to appear for study visits without st ating an intention to withdraw), the investigator should show 
"due diligence" by documenting in the source documents steps taken to contact the patient, e.g. 
dates of telephone calls, registered letters, etc.  
If premature withdrawal occurs for any reason,  the investigator must make every effort to 
determine the primary reason for a patient ’s premature withdrawal from the study and record this 
information with the patient ’s research data in REDCap as well as rep ort this withdrawal to the 
Institutional Revie w Board  and FDA CDER,  if deemed necessary by the committee.  
Patients will be considered to have completed the study if they attend all protocol specified visits 
and complete all assessments. A patient who discontinues the study medication for any reason, 
including an adverse event must complete a Safety Follow -Up visit. Any patient still in sc reening 
at the time 50 patients have been enrolled will be allowed to continue screening to determine if 
they will be eligible to enter the study, provided all screen ing assessments are complete and the 
randomization visit can occur on or before the designated end of subject recruitment date. The 
investigator must provide follow -up medical care for all patients who are prematurely withdrawn 
from the study or must refer  them for appropriate ongoing care.  
The study can be terminated at any time for any reason by the investigator. Should this be 
necessary, each patient should be seen as soon as possible and treated as described for a 
prematurely withdrawn patient. The inv estigator may be informed of additional procedures to be 
followed in order to ensure that adequate consideration is given to the protection of the patient ’s 
interests. The investigator will be responsible for informing the Committee on Human Research of 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 37 of 43 
Protocol Template Effective: 07 JAN 2015  the trial ’s early termination .  
 
15 STATISTICAL METHODS AND CONSIDERATIONS  
Prior to the analysis of the final study data, a detailed Statistical Analysis Plan (SAP) will be 
written describing all analyses that will be performed.  The SAP will contain any modifications to 
the analysis plan described below.   
15.1 Data Sets Analyzed  
All eligible patients who are randomized into the study and receive at least one dose of the study 
drug (the Safety Population) will be included in the safety analysis.  
15.2 Demographic and Baseline Characteristics  
The following demographic variables at screening will be summarized by dose level: race, gender, 
age, height and weight.   
15.3 Analysis of Primary Endpoint  
Data will be analyzed per protocol utilizing an intention to treat approach including all patients 
randomized to the study for the principal analysis. Lo ss to follow up will be accounted for using 
standard statistical methods. The principal analysis will be performed using mixed effects linear 
regression model controlling for clustering by eye.  
15.4 Analysis of Secondary Endpoints  
Secondary endpoints will be an alyzed using the same methods as primary endpoints.  
Safety and tolerability data will be summarized by treatment group.    
Adverse event rates will be coded by body system and MedDra classification term.  Adverse 
events will be tabulated by treatment group  and will include the number of patients for whom the 
event occurred, the rate of occurrence, and the severity and relationship to study drug.    
15.5 Interim Analysis  
After each patient completes the Week 6 phone call, the side effects reported will be analyzed.  
When 50% of patients have completed the study through Study Visit 2 (total visit 3), an interim 
analysis for safety will be conducted by the PI.  
Serious adverse events will be monitored by the committee on an ongoing basis throughout the 
study.  
15.6 Sample Size and Randomization  
With 25  patients per group , the study has 90% power to detect a 50% relative reduction in latency 
with BZA compared to placebo  at the 3 -month out come for group 1 assuming a two -sided test 
with alpha = 0.05. Study size may be expanded to compensate for dropouts over the short study 
period. To maximize study efficiency and resource utilization these subjects will not be enrolled 
unless necessary.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 38 of 43 
Protocol Template Effective: 07 JAN 2015  16 DATA COLLECTION, RET ENTION AND MONITORIN G 
16.1 Data Collection Instruments  
The Investiga tor will prepare and maintain adequate and accurate source documents designed to 
record all observations and other pertinent data for each subject treated with the study drug.   
Study personnel at each site will enter data from source documents correspondi ng to a subject’s 
visit into the protocol -specific electronic Case Report Form (eCRF) when the information 
corresponding to that visit is available.  Subjects will not be identified by name in the study 
database or on any study documents to be collected by  the Sponsor (or designee), but will be 
identified by a site number, subject number and initials.  
If a correction is required for an eCRF, the  time and date stamps track the person entering or 
updating eCRF data and creates an electronic audit trail.   
The Investigator is responsible for all information collected on subjects enrolled in this study.  All 
data collected during the course of this study must be reviewed and verified for completeness and 
accuracy by the Investigator.  A copy of the CRF will rema in at the Investigator’s site at the 
completion of the study.  
16.2 Data Management Procedures  
The data will be entered into a validated database.  The Data Management group will be 
responsible for data processing, in accordance with procedural documentation.  D atabase lock will 
occur once quality assurance procedures have been completed.  
All procedures for the handling and analysis of data will be conducted using good computing 
practices meeting FDA guidelines for the handling and analysis of data for clinical t rials.  
16.3 Data Quality Control and Reporting  
After data have been entered into the study database, a system of computerized data validation 
checks will be implemented and applied to the database on a regular basis. Queries are entered, 
tracked, and resolved t hrough the EDC system directly. The study database will be updated in 
accordance with the resolved queries.  All changes to the study database will be documented.  
16.4 Archival of Data  
The database is safeguarded against unauthorized access by established secur ity procedures; 
appropriate backup copies of the database and related software files will be maintained.   
Databases  are backed up by the database administrator in conjunction with any updates or changes 
to the database.    
At critical junctures of the proto col (e.g., production of interim reports and final reports), data for 
analysis is locked and cleaned per established procedures.  
16.5 Availability and Retention of Investigational Records  
The Investigator must make study data accessible to the monitor, other au thorized representatives 
of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) inspectors upon 
request.  A file for each subject must be maintained that includes the signed Informed Consent, 
HIPAA Authorization and Assent Form and copies  of all source documentation related to that 
subject.  The Investigator must ensure the reliability and availability of source documents from 
which the information on the CRF was derived.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 39 of 43 
Protocol Template Effective: 07 JAN 2015  All study documents (patient files, signed informed consent forms, c opies of CRFs, Study File 
Notebook, etc.) must be kept secured for a period of two years following marketing of the 
investigational product or for two years after centers have been notified that the IND has been 
discontinued.  There may be other circumstan ces for which the Sponsor is required to maintain 
study records and, therefore, the Sponsor should be contacted prior to removing study records for 
any reason.  
16.6 Monitoring  
Monitoring visits will be conducted by representatives of the Sponsor according to the U.S. CFR 
Title 21 Parts 50, 56, and 312 and ICH Guidelines for GCP (E6).    By signing this protocol, the 
Investigator grants permission to the Sponsor (or designee), an d appropriate regulatory authorities 
to conduct on -site monitoring and/or auditing of all appropriate study documentation.  
16.7 Subject Confidentiality  
In order to maintain subject confidentiality, only a subject number and subject initials will identify 
all study subjects on CRFs and other documentation submitted to the Sponsor.  Additional subject 
confidentiality issues (if applicable) are covered in the Clinical Study Agreement.  
17 ADMINISTRATIVE, ETHI CAL, REGULATORY CONS IDERATIONS  
The study will be conducted according to the Declaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical 
Investigators (21 CFR 312).  
To maintain confidentiality, all laboratory specimens, evalu ation forms, reports and other records 
will be identified by a coded number and initials only.  All study records will be kept in a locked 
file cabinet and code sheets linking a patient’s name to a patient identification number will be 
stored separately in  another locked file cabinet.  Clinical information will not be released without 
written permission of the subject, except as necessary for monitoring by the FDA.  The 
Investigator must also comply with all applicable privacy regulations (e.g., Health Insu rance 
Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC).  
17.1 Protocol Amendments  
Any amendment to the protocol will be written by PI.  Protocol amendments cannot  be 
implemented without prior written IRB/IEC approval except as n ecessary to eliminate immediate 
safety hazards to patients.  A protocol amendment intended to eliminate an apparent immediate 
hazard to patients may be implemented immediately, provided the IRBs are notified within five 
working days.  
17.2 Institutional Review B oards and Independent Ethics Committees  
The protocol and consent form will be reviewed and approved by the IRB/IEC prior to study 
initiation.  Serious adverse experiences regardless of causality will be reported to the IRB/IEC in 
accordance with the standa rd operating procedures and policies of the IRB/IEC, and the 
Investigator will keep the IRB/IEC informed as to the progress of the study.  The Investigator will 
obtain assurance of IRB/IEC compliance with regulations.  
Any documents that the IRB/IEC may nee d to fulfill its responsibilities (such as protocol, protocol 
amendments, Investigator’s Brochure, consent forms, information concerning patient recruitment, 
payment or compensation procedures, or other pertinent information) will be submitted to the 
IRB/I EC.  The IRB/IECs written unconditional approval of the study protocol and the informed 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 40 of 43 
Protocol Template Effective: 07 JAN 2015  consent form will be in the possession of the Investigator before the study is initiated. This 
approval must refer to the study by exact protocol title and number and s hould identify the 
documents reviewed and the date of review.  
Protocol and/or informed consent modifications or changes may not be initiated without prior 
written IRB/IEC approval except when necessary to eliminate immediate hazards to the patients or 
when  the change(s) involves only logistical or administrative aspects of the study.  Such 
modifications will be submitted to the IRB/IEC and written verification that the modification was 
submitted and subsequently approved should be obtained.   
The IRB/IEC mu st be informed of revisions to other documents originally submitted for review; 
serious and/or unexpected adverse experiences occurring during the study in accordance with the 
standard operating procedures and policies of the IRB; new information that may affect adversely 
the safety of the patients of the conduct of the study; an annual update and/or request for re -
approval; and when the study has been completed.  
17.3 Informed Consent Form  
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, US 
Code of Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, 
and CFR Part 56, Subpart A), the Health Insurance Portability and Accountability Act (HIPAA, if 
applicable), and local regulations.  
The Invest igator will prepare the informed consent form, assent and HIPAA authorization and 
provide the documents to the Sponsor or designee for approval prior to submission to the 
IRB/IEC.  The consent form generated by the Investigator must be acceptable to the Sp onsor and 
be approved by the IRB/IEC.  The written consent document will embody the elements of 
informed consent as described in the International Conference on Harmonisation and will also 
comply with local regulations. The Investigator will send an IRB/IE C-approved copy of the 
Informed Consent Form to the Sponsor (or designee) for the study file.  
A properly executed, written, informed consent will be obtained from each subject prior to 
entering the subject into the trial.  Information should be given in bo th oral and written form and 
subjects must be given ample opportunity to inquire about details of the study.  If appropriate and 
required by the local IRB/IEC, assent from the subject will also be obtained.  If a subject is unable 
to sign the informed cons ent form (ICF) and the HIPAA authorization, a legal representat ive may 
sign for the subject.  A copy of the signed consent form (and assent) will be given to the subject 
and the original will be maintained with the subject’s records.  
17.4 Publications  
The prep aration and submittal for publication of manuscripts containing the study results shall be 
in accordance with a process determined by mutual written agreement among the study Sponsor 
and participating institutions.  The publication or presentation of any s tudy results shall comply 
with all applicable privacy laws, including, but not limited to, the Health Insurance Portability and 
Accountability Act of 1996.  
17.5 Investigator Responsibilities  
By signing the Agreement of Investigator form, the Investigator agree s to: 
1. Conduct the study in accordance with the protocol and only make changes after 
notifying the Sponsor (or designee), except when to protect the safety, rights or welfare 
of subjects.  
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 41 of 43 
Protocol Template Effective: 07 JAN 2015  2. Personally conduct or supervise the study (or investigation).  
3. Ensure that the requirements relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as stated in § 21 CFR, parts 50 and 56.  
4. Report to the Sponsor or designee any AEs that occur in the course of the study , in 
accordance with §21 CFR 312.64.  
5. Ensure that all associates, colleagues and employees assisting in the conduct of the study 
are informed about their obligations in meeting the above commitments.  
6. Maintain adequate and accurate records in accordance with §21 CFR 312.62 and to 
make those records available for inspection with the Sponsor (or designee).  
7. Ensure that an IRB that complies with the requirements of §21 CFR part 56 will be 
responsible for initial and continuing review and approval o f the clinical study.  
8. Promptly report to the IRB and FDA CDER  all changes in the research activity and all 
unanticipated problems involving risks to subjects or others (to include amendments and 
IND safety reports).  
9. Seek IRB approval before any changes are  made in the research study, except when 
necessary to eliminate hazards to the patients/subjects.  
10. Comply with all other requirements regarding the obligations of clinical investigators 
and all other pertinent requirements listed in § 21 CFR part 312.  
 
 
 
APPENDIX 1 . SCHEDULE OF STUDY VISITS  
 SCREENING  
VISIT 1 
(Screen)a STUDY1  
VISIT 2 
(Baseline)a STUDY2  
VISIT 3 
(Month 3)a STUDY 3 
VISIT 4 
(MONTH 6) 
Informed Consent  X    
Medical History  X    
Complete Physical Exam  X    
Abbreviated Physical Exam   X X X 
Height  X    
Weight  X    
Vital Signs  X X X X 
Pregnancy Test (Serum)  X    
Hematology  X  X X 
Chemistry  X   X 
Research blood stored  X X X X 
Neurological + 
ophthalmological exam with 
neurologist   X X X 
Riley M. Bovc  Confidential  
 
Version #:  Version Date:  Page 42 of 43 
Protocol Template Effective: 07 JAN 2015  Safety phone call at Week 6.  
 
** **In rare cases during the initial visit, the patient may be asked to undergo an electroretinogram. This test 
measures the electrical response of the eye ’s light -sensitive cells, called rods and cones. These cells are part 
of the retina (the back part of the eye). This test is used to detect disorders of the retina. For this study, this 
option exists only to be used in cases where more information is needed  to confirm a diagnosis of optic 
neuritis. The test is performed by placing numbing drops in the patient ’s eyes, so that  there is no discomfort. 
Then, the patient ’s eyes are held open with a small device called a retractor. An electrical sensor (electrode)  
is placed on each eye and the electrical activity of the retina is recorded in  response to light. The primary 
risk associated with the study is a temporary scratch of the surface of the cornea due to the electrode. 
Otherwise, there are no risks associated  with this procedure.  
 MRI   X X X 
Randomization  X    
Dispensing of Study Drug   X X  
Counting of Returned Study 
Drug     X 
Initiate Subject Diary  X    
Subject Diary Review   X X X 
Concomitant Medication 
Review  X X X X 
Additional cognitive 
assessments   X X X 
OCT  X X  X 
VEP  X X X X 
Vision testing (high, low 
contrast)   X X X 
Cone contrast   X X X 
VFQ   X X X 
Questionnaires (MFIS, 
MSWS12, SF-36)  X X X 
Assess likely side effects   X X X 
EDSS   X X X 
SDMT   X X X 
Timed walking tests    X X X 
ERG** (optional)  X    
Protocol Number  Confidential  
 
Version #:  Version Date: Date   Page 43 of 43 
Protocol Template © CFFT TDN   Effective: 12 SEP  2007   